(alphaS)-alpha-氨基环己烷乙酸叔丁酯盐酸盐 | 213475-52-6

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (alphaS)-alpha-氨基环己烷乙酸叔丁酯盐酸盐
• 中文别名: L-环己基甘氨酸叔丁酯盐酸盐
• 英文名称: Fmoc-Asp(otBu)-Wang resin
• 英文别名: (S)-tert-Butyl 2-amino-2-cyclohexylacetate hydrochloride；tert-butyl (2S)-2-amino-2-cyclohexylacetate;hydrochloride
• CAS: 213475-52-6
• 化学式: C₂₃H₂₄NO₆Pol
• 分子量: 249.78
• InChiKey: IAOLQNWJPAWXBA-PPHPATTJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Chg-OtBu HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Chg-OtBu HCl
CAS number: 213475-52-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H23NO2.ClH
Molecular weight: 249.8

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (alphaS)-alpha-氨基环己烷乙酸叔丁酯盐酸盐 在 magnesium iodide 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以96%的产率得到Fmoc-L-天冬氨酸
  参考文献：
  名称：

  MgI2介导的保护基团的化学选择性切割：常规脱保护方法的替代方法

  摘要：

  在此描述了MgI 2作为定量和轻度化学选择性切割保护基的有价值工具的范围。这种新颖的合成方法扩大了保护基的使用范围，拓宽了合成过程中正交性的概念，并提供了从固体载体上释放化合物的简便机会。

  DOI：

  10.1002/chem.201501799
• 作为产物：
  描述：

  Fmoc-L-天冬氨酸 beta-叔丁酯 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 、 哌啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.25h， 生成 (alphaS)-alpha-氨基环己烷乙酸叔丁酯盐酸盐
  参考文献：
  名称：

  Triazolo [1,5-a] [1,4] diazepin-6-ones的无铜固相合成

  摘要：

  本文报道了在固体载体上合成三唑并[1,5- a ] [1,4]二氮杂-6-6。使用Mitsunobu烷基化条件，将固定在Wang树脂上的氨基酸进行炔丙基化，然后用炔丙醇，2--2-炔-1-醇或其他3-苯基丙-2-炔-1-醇进行烷基化。脱腺苷基化后，用Fmoc-叠氮丙氨酸酰化可生成线性前体，将其在树脂上热环化，得到固定的三唑二氮杂酮。从聚合物载体上裂解后，以高的粗纯度和良好的总收率获得目标化合物。此外，该合成方法适用于方便固相合成的寡肽，该寡肽含有三唑并二氮杂吡啶酮部分作为拟肽杂环约束。

  DOI：

  10.1002/adsc.202001403

文献信息

• Elucidating the Structural Requirement of Uridylpeptide Antibiotics for Antibacterial Activity
  作者：Yuma Terasawa、Chisato Sataka、Toyotaka Sato、Kazuki Yamamoto、Yukari Fukushima、Chie Nakajima、Yasuhiko Suzuki、Akira Katsuyama、Takanori Matsumaru、Fumika Yakushiji、Shin-ichi Yokota、Satoshi Ichikawa

  DOI：10.1021/acs.jmedchem.0c00973

  日期：2020.9.10

  The synthesis and biological evaluation of analogues of uridylpeptide antibiotics were described, and the molecular interaction between the 3′-hydroxy analogue of mureidomycin A (3′-hydroxymureidomycin A) and its target enzyme, phospho-MurNAc-pentapeptide transferase (MraY), was analyzed in detail. The structure–activity relationship (SAR) involving MraY inhibition suggests that the side chain at the

  描述了尿苷肽抗生素类似物的合成和生物学评估，并证明了莫来霉素A（3'-羟基尿素霉素A）的3'-羟基类似物与其靶酶磷酸-MurNAc-五肽转移酶（MraY）之间的分子相互作用。详细分析。涉及MraY抑制的结构活性关系（SAR）表明，尿素-二肽部分的侧链不影响MraY抑制。但是，抗铜绿假单胞菌活性形成了鲜明的对比，而尿素-二肽基序是关键的贡献者。还建议核苷肽渗透酶NppA1A2BCD负责3'-羟基mureidomycin A进入细胞质的转运。进一步进行了3'-羟基mureidomycin A尿素-二肽部分的系统SAR分析，并确定了抗菌活性。该研究为基于尿苷肽抗生素的类似物的合理设计提供了指导。
• Discovery of a novel small molecule agonist scaffold for the APJ receptor
  作者：Sanju Narayanan、Rangan Maitra、Jeffery R. Deschamps、Katherine Bortoff、James B. Thomas、Yanyan Zhang、Keith Warner、Vineetha Vasukuttan、Ann Decker、Scott P. Runyon

  DOI：10.1016/j.bmc.2016.06.018

  日期：2016.8

  coupled apelin receptor (APJ, AGTRL-1, APLNR). The APJ receptor is an attractive therapeutic target because of its involvement in cardiovascular diseases and potentially other disorders including liver fibrosis, obesity, diabetes, and neuroprotection. To date, pharmacological characterization of the APJ receptor has been limited due to the lack of small molecule functional agonists or antagonists.

  Apelinergic系统包括一系列内源性肽apelin，ELABELA / TODDLER及其7跨膜G蛋白偶联apelin受体（APJ，AGTRL-1，APNLR）。APJ受体是一种有吸引力的治疗靶标，因为它参与了心血管疾病和潜在的其他疾病，包括肝纤维化，肥胖，糖尿病和神经保护。迄今为止，由于缺乏小分子功能性激动剂或拮抗剂，APJ受体的药理学表征受到限制。通过重点筛选，我们确定了一种药物样小分子激动剂，其功能EC 50值为21.5±5μM，结合亲和力（K i）为5.2± 0.5μM，命中1。初步的结构活性研究提供了化合物具有效力增强27倍的22和第一亚微摩尔全激动剂，EC 50值为800±0.1 nM，K i为1.3±0.3μM。初步的SAR，合成方法和体外药理学表征表明，该支架将成为进一步改善APJ效能和选择性的有利起点。 下载：下载全图
• Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression
  作者：Vishnu C. Damalanka、Jorine J. L. P. Voss、Matthew W. Mahoney、Tina Primeau、Shunqiang Li、Lidija Klampfer、James W. Janetka

  DOI：10.1021/acs.jmedchem.1c01671

  日期：2021.12.23

  series of cyclic tripeptides has superior metabolic stability and significantly improved pharmacokinetics in mice relative to the corresponding linear peptides. We identified the lead compound VD2173 that potently inhibits matriptase and hepsin, which was tested in parallel alongside the acyclic inhibitor ZFH7116 using both in vitro and in vivo models of lung cancer. We demonstrated that both compounds block

  肝细胞生长因子 (HGF) 是 MET 受体酪氨酸激酶的配体，是肿瘤微环境中丰富的促肿瘤因子。一种或多种丝氨酸内肽酶matriptase、hepsin和HGF激活剂对无活性pro-HGF的蛋白水解激活是HGF/MET信号传导中的限速步骤。在此，我们合理设计了一类新型侧链环化大环肽抑制剂。相对于相应的线性肽，新系列的环状三肽具有优越的代谢稳定性和显着改善的小鼠药代动力学。我们确定了有效抑制matriptase和hepsin的先导化合物VD2173，并在体外和体内肺癌模型中与无环抑制剂ZFH7116同时进行了测试。我们证明了这两种化合物都能阻断 pro-HGF 活化，消除 HGF 介导的伤口愈合，并克服肺癌模型中对 EGFR 和 MET 靶向治疗的耐药性。此外，VD2173 抑制小鼠肺癌肿瘤的 HGF 依赖性生长。
• HCV PROTEASE INHIBITORS AND USES THEREOF
  申请人：Green Brian E.

  公开号：US20100029686A1

  公开（公告）日：2010-02-04

  This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.

  这项发明涉及：(a) 公式I的化合物及其盐，它们可用作丙型肝炎病毒（HCV）抑制剂；(b) 用于制备这种化合物和盐的中间体；(c) 包含这种化合物和盐的药物组合物；以及(d) 使用这种化合物、盐和组合物的方法。
• 一种葡萄糖敏感自律式胰岛素释放微凝胶载 体及其制备方法
  申请人：湖北大学

  公开号：CN104586752B

  公开（公告）日：2017-09-01

  本发明提供一种葡萄糖敏感自律式胰岛素释放微凝胶载体及制备方法，本发明所述的葡萄糖敏感自律式胰岛素释放载体由3‑丙烯酰氨基苯硼酸、含乙烯基功能基团的亲水性RGD多肽、N‑异丙基丙烯酰胺三种单体经自由基聚合获得葡萄糖敏感纳米凝胶，所述葡萄糖敏感纳米凝胶再与胰岛素组合得到载药微凝胶。本发明提供的葡萄糖敏感自律式胰岛素释放微凝胶载体能够实现体温下依葡萄糖浓度变化而自动“开‑关”释放胰岛素。